查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103867

肺炎治療市場：全球市場預測，2026-2032年

Pneumonia Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肺炎治療市場將成長至 67.4 億美元，複合年成長率為 8.89%。

主要市場統計數據
基準年 2025 37.1億美元
預計年份：2026年 40.4億美元
預測年份 2032 67.4億美元
複合年成長率 (%) 8.89%

肺炎持續影響兒童、老年人、免疫力缺乏者以及患有慢性心肺疾病的人群，因此肺炎治療是感染疾病控制的關鍵優先事項。世界衛生組織（WHO）將肺炎列為五歲以下兒童感染疾病死亡的主要原因之一，而老年人罹患重症、住院治療和併發症的風險更高。治療策略取決於病原體類型、疾病嚴重程度、治療環境、疫苗接種情況、抗生素抗藥性風險、共病以及當地臨床指引。關鍵治療方法包括經驗性和針對性抗生素治療、在確定病毒病因後進行抗病毒治療、對某些免疫力缺乏患者群體進行抗真菌治療、氧氣療法、在臨床適用時進行抗炎治療，以及開展免疫接種計劃以降低嚴重肺炎球菌肺炎、流感相關性肺炎、呼吸道融合細胞病毒（RSV）相關性肺炎和COVID-19相關性肺炎的發生率。肺炎治療的未來前景越來越取決於快速診斷、合理使用抗生素、更廣泛地獲得有效藥物、氧氣供應以及綜合護理路徑的需求，這些措施可以減少可避免的併發症，同時縮短開始適當治療的時間。

肺炎治療前景的變革性變化

在肺炎治療領域，治療模式正經歷著從廣泛經驗性治療轉向更快速、更精準的治療轉變，並遵循合理的抗生素使用指南。隨著抗生素抗藥性的日益增強，人們對最佳化抗生素選擇、基於實證醫學縮短療程以及更準確地鑑別細菌性、病毒性、真菌性、吸入性肺炎和混合性肺炎的需求也日益成長。分子診斷、即時檢測、呼吸道病原體檢測、生物標記以及改進的微生物學工作流程正在影響處方行為，使治療方案能夠更早升級或降級。疫苗接種政策也正在重塑治療需求，透過減少可預防的重症疾病，特別是針對肺炎球菌、流感、呼吸道融合細胞病毒、b型流感嗜血桿菌和COVID-19的預防策略，降低了治療需求。儘管醫院已針對社區獲得性肺炎、醫院獲得性肺炎、人工呼吸器相關性肺炎和吸入性肺炎實施了標準化治療方案，但門診機構越來越重視風險分層、藥物依從性以及最大限度地減少不必要的抗生素暴露。這些變化正在強化實證方案、真實世界監測、感染預防以及感染疾病專家、肺科醫生、藥劑師、重症監護專家、微生物學家、急診醫生和基層醫療醫生等多學科協作的作用。

人工智慧對肺炎治療的累積影響

人工智慧 (AI) 正在透過改進臨床分診、診斷結果解讀、輔助抗生素使用決策以及最佳化營運系統，對肺炎治療產生深遠影響。 AI 驅動的影像工具能夠識別胸部 X 光片和電腦斷層掃描中與肺炎相符的觀察表現，與臨床醫生的確認相結合，可在急診、醫院和資源匱乏的環境中實現更快速的評估。目前正在進行的研究旨在利用機器學習模型、臨床變數、實驗室數值、氧合指標、影像學觀察和電子健康記錄資料來預測疾病嚴重程度、重症監護需求、死亡風險、再入院風險、敗血症進展以及治療失敗的可能性。在抗生素使用方面，AI 可以幫助識別不恰當的治療方案，識別需要降階治療的患者，支持考慮區域抗生素抗藥性的處方，並在與微生物系統整合時，提高培養和藥敏試驗結果的及時確認。此外，AI 還透過分子標靶篩檢、宿主-病原體相互作用建模、化合物優先排序以及對臨床試驗和真實世界數據的分析，支持藥物發現和現有藥物的再利用研究。然而，由於肺炎的治療結果尤其對及時準確的治療決策高度敏感，因此實施過程中必須解決演算法偏差、數據品質、可解釋性、網路安全、監管檢驗、融入工作流程以及臨床醫生監督等挑戰。

關於肺炎治療的關鍵區域見解

在亞太地區，肺炎治療受到多種因素的影響，例如呼吸道感染疾病負擔沉重、都市區密度高、部分經濟體人口老化、醫院基礎設施不斷擴建，以及在診斷、氧氣療法和先進抗生素使用方面存在差異。兒童和老年人口眾多的國家繼續優先考慮疫苗接種、早期治療和改進基層醫療轉診系統，同時抗菌藥物抗藥性監測仍然是合理使用抗生素的關鍵。在歐洲，指引指導下的治療、疫苗接種政策、跨境抗菌藥物抗藥性監測和醫院抗生素使用管理受到重視，並日益關注減少不合理使用抗生素以及改善老年人、長期照護機構居民和慢性疾病患者的治療效果。在北美，實證臨床指南、先進的診斷平台、重症監護方案、疫苗接種計劃和抗生素使用管理得到積極實施，肺炎管理與抗生素抗藥性監測、呼吸道病毒爆發和品質改進工作密切相關。拉丁美洲面臨雙重挑戰：既要提高基本抗生素、氧氣和呼吸道照護的可近性，也要同時加強公共和私人醫療系統的診斷能力和抗藥性監測。非洲持續面臨肺炎的沉重負擔，尤其是在兒童和弱勢成年人群體中。在這些地區，獲得基本藥物、脈搏血氧計、氧氣療法、免疫接種、診斷和社區層面的病例管理是提高治療效果的關鍵。在中東，儘管對現代化醫院系統、重症監護能力、感染預防和感染疾病應對措施的投資正在不斷推進，但人口流動、合併症模式、抗生素抗藥性風險以及不同醫療機構間服務可及性的差異仍然影響著肺炎的治療。

關於肺炎治療的關鍵群體特異性發現

在北約成員國中，肺炎治療受到緊急準備、軍事醫療系統、生物安全計畫和呼吸道感染疾病應變措施的影響，尤其是在那些擁有完善的醫院網路、儲備物資和重症監護方案的國家。七國集團（G7）國家通常擁有先進的監管體系、強大的臨床研究能力、完善的免疫接種計劃、較高的合理用藥框架採納率以及廣泛的診斷服務；然而，人口老齡化、病毒性呼吸道感染疾病激增以及抗藥性感染疾病持續給治療帶來壓力。金磚國家在肺炎治療方面構成了一個多元化但至關重要的群體，它們擁有大規模的患者群體、國內藥品生產能力、不斷擴展的醫院網路、對感染疾病監測的重視，以及在公平獲得診斷、氧氣和最佳化治療方面持續存在的差距。歐盟受益於協調一致的衛生政策機制、抗菌素抗藥性計畫、藥物安全監測系統、免疫接種策略以及支持合理使用抗生素和疫苗預防的統一臨床指南。在東協地區，肺炎治療受到多種因素的影響，包括醫療體系的多樣性、熱帶地區的感染疾病模式、對抗生素抗藥性的擔憂、不斷擴大的免疫接種計劃，以及確保患者能夠獲得價格合理的診斷和一線、二線治療的需求。在海灣合作理事會（GCC）國家，對三級醫療、數位醫療、感染預防以及呼吸和重症監護專科服務的投入增加，正在支持對重症肺炎、醫院感染和合併複雜疾病的患者進行更多基於規範的肺炎治療。

針對特定國家的肺炎治療重點見解。

在中國，隨著醫院容量、感染疾病監測、免疫接種工作和國家治療能力的持續提升，肺炎治療的重點包括抑制抗生素抗藥性、快速診斷以及改善城鄉地區的醫療服務可近性。在美國，肺炎治療環境高度規範化，有臨床指南、多種診斷工具、強制性合理使用抗生素、免疫接種計劃以及對社區獲得性肺炎、醫院獲得性肺炎和人工呼吸器相關性肺炎的重點管理作為支撐。在日本，隨著人口老化，對肺炎預防、吸入性肺炎管理、疫苗接種、改善吞嚥功能的干預措施和長期護理以及在急長期護理中謹慎使用抗生素的需求日益成長。在印度，肺炎負擔沉重，且醫療服務可及性因地區而異，價格合理的抗生素、氧氣供應、疫苗接種、診斷、轉診途徑以及合理使用抗生素對於改善治療效果至關重要。德國受益於完善的醫院基礎設施、專業的醫療服務、微生物檢測能力和系統化的抗生素使用，這些都支持針對性治療和管理複雜的肺炎病例。英國強調以指南為基礎的處方、全國範圍內的抗生素使用、免疫接種、快速評估途徑以及初級和醫院護理的綜合管理。澳洲在健全的疫苗接種計劃、抗生素使用規範、三級醫療體系和呼吸道疾病監測方面具有優勢，但遍遠地區的醫療服務可近性以及解決原住民的健康差距仍然是重大挑戰。法國結合了強力的公共衛生政策、疫苗接種工作、藥物安全監測和以醫院為基礎的感染疾病專家團隊，以促進合理治療和預防主導的照護。韓國擁有先進的醫院基礎設施、診斷技術、數位醫療應用、感染控制措施和抗生素使用活動，這些都為日益精準的肺炎治療方案提供了支持。義大利和西班牙老年人口眾多，因此在醫院和長期照護機構中，預防、早期診斷、疫苗接種、吸入性肺炎風險管理和重症肺炎的有效治療尤其重要。加拿大強調公共衛生預防、疫苗接種、合理使用抗生素以及在其地理分散的人口（包括偏遠地區和原住民社區）中公平地獲得醫療服務。俄羅斯的肺炎治療現狀受到區域醫療保健差異、呼吸道感染疾病負擔、醫院容量差異以及持續獲得診斷和最佳化抗生素使用等因素的影響。巴西不同地區都面臨嚴重的呼吸道感染疾病負擔，其治療重點在於疫苗接種、抗生素取得、氧氣療法、醫院準備以及抗菌素抗藥性監測。墨西哥正透過擴大公共衛生服務、加強免疫接種工作以及改善基本抗生素的獲取途徑來加強肺炎治療，但診斷方法的差異仍然是治療中需要考慮的重要因素。

為行業領導者提供的實用建議

產業領導者應優先考慮兼顧臨床療效、合理使用抗生素、安全性和可及性的肺炎治療策略。研發和商業化計畫應充分考慮當地的抗菌藥物抗藥性模式、指南建議、診斷手段的可及性、疫苗接種率，以及日益成長的區分細菌性肺炎與病毒性、真菌性、吸入性肺炎和混合感染的需求。相關人員應投資於高風險族群（包括老年人、兒童、免疫力缺乏患者、慢性呼吸系統或心血管疾病患者以及重症監護和長期照護機構的患者）的實證研究。與醫療保健系統合作可以加強抗菌藥物使用教育、藥物安全監測、真實世界療效追蹤以及快速診斷的合理應用。各機構也應支持治療依從性計畫、改善氧氣取得途徑的努力，以及適用於門診、住院、兒童和重症監護的多種劑型。為了保持長期競爭力，領導者應專注於解決抗菌素抗藥性、廣泛的地域可及性、確保基本藥物的持續供應以及具有臨床意義的終點（例如重症肺炎的臨床穩定時間、減少併發症、縮短住院時間、降低治療失敗率和提高生存率）的創新。

調查方法

本執行摘要採用系統性的二手調查方法編寫，並專注於檢驗的公共衛生、臨床、監管和科學資訊來源。輸入資料包括國際和國家肺炎治療指南、抗菌藥物抗藥性監測數據、免疫政策參考資料、同行評審的臨床文獻、公共衛生機構出版刊物、監管安全資訊、基本藥物參考資料、呼吸系統疾病監測以及醫院合理使用抗菌藥物的指南。分析採用資訊來源三角驗證法，檢驗不同地區、國家醫療保健環境、臨床路徑、醫療機構和疾病類型（社區獲得性肺炎、醫院獲得性肺炎、人工呼吸器相關性肺炎、吸入性肺炎、病毒性肺炎、真菌性肺炎、重症細菌性肺炎等）的治療實務。特別關注治療方案、診斷方法應用、預防策略、抗菌藥物抗藥性管理、氧氣療法和支持治療的可近性以及醫療保健系統應對能力等方面的數據支援趨勢。本調查方法不包括推測性的市場規模估算、收入估算、市場佔有率排名和預測。相反，它側重於對影響整個醫療保健系統肺炎治療決策的因素進行循證解釋。

結論

肺炎治療正朝著更快的診斷、更精準的治療選擇、更有效的合理使用抗生素以及以預防主導的疾病控制方向發展。最重要的策略主題包括：控制抗生素抗藥性、改善基本抗生素和氧氣療法的可近性、整合快速診斷、提高疫苗接種的有效性，以及滿足兒童、老年人、免疫力缺乏、慢性疾病患者患者和重症監護患者等高風險族群的需求。醫療基礎設施、公共衛生政策、抗藥性監測、診斷能力、氧氣供應和經濟承受能力等方面的區域和國家差異，持續影響治療方案的選擇。人工智慧、真實世界數據、數位化臨床決策支援和先進的監測系統，如果其有效性得到檢驗並得到負責任的實施，則可以改善肺炎的管理。對於產業相關人員，最大的機會在於提供臨床差異化、符合合理使用抗生素原則、易於取得且供應可靠的解決方案，從而改善社區醫療、醫院和重症監護環境中病患的治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 肺炎治療市場：依產品分類

  • 製藥
    • 抗生素
    • 抗病毒藥物
    • 抗真菌藥物
  • 疫苗
    • 肺炎鏈球菌疫苗
    • 流感疫苗

第8章：肺炎治療市場：依傳播途徑分類

  • 社區型肺炎（CAP）
  • 院內獲得性肺炎（HAP）
  • 人工呼吸器相關性肺炎（VAP）
  • 吸入性肺炎

第9章 肺炎治療市場：依給藥途徑分類

  • 口服
  • 靜脈注射（IV）
  • 肌肉內注射（IM）
  • 吸入

第10章：肺炎治療市場：依年齡層別分類

  • 兒童
  • 成人
  • 老年人

第11章 肺炎治療市場：依通路分類

  • 線上
  • 離線

第12章 肺炎治療市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章 肺炎治療市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章 肺炎治療市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biobrick Pharma Private Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Hikma Pharmaceuticals PLC
  • Lincoln Pharmaceuticals Limited
  • Mankind Pharma Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Private Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Wellona Pharma Private Limited
Product Code: MRR-8E22B61932B6

The Pneumonia Therapeutics Market is projected to grow by USD 6.74 billion at a CAGR of 8.89% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.71 billion
Estimated Year [2026] USD 4.04 billion
Forecast Year [2032] USD 6.74 billion
CAGR (%) 8.89%

Pneumonia therapeutics remain a critical priority across infectious disease management as pneumonia continues to affect children, older adults, immunocompromised patients, and individuals with chronic cardiopulmonary conditions. The World Health Organization identifies pneumonia as a leading infectious cause of death among children under five, while older adults face elevated risks of severe disease, hospitalization, and complications. Treatment strategies are shaped by pathogen type, disease severity, care setting, vaccination status, antimicrobial resistance risk, comorbidities, and local clinical guidelines. Core therapeutic approaches include empiric and targeted antibacterial therapy, antiviral treatment for confirmed viral etiologies, antifungal therapy in selected immunocompromised populations, oxygen support, anti-inflammatory management where clinically appropriate, and preventive immunization programs that reduce severe pneumococcal, influenza-associated, respiratory syncytial virus-associated, and COVID-19-related pneumonia. The executive outlook for pneumonia therapeutics is increasingly defined by the need for rapid diagnosis, antimicrobial stewardship, broader access to effective medicines, oxygen availability, and integrated care pathways that shorten time to appropriate therapy while reducing avoidable complications.

Transformative Shifts in the Pneumonia Therapeutics Landscape

The pneumonia therapeutics landscape is undergoing a structural shift from broad empiric treatment toward faster, more precise, and stewardship-aligned care. Rising antimicrobial resistance has intensified demand for optimized antibiotic selection, shorter evidence-based treatment durations, and better differentiation between bacterial, viral, fungal, aspiration-related, and mixed pneumonia. Molecular diagnostics, point-of-care testing, respiratory pathogen panels, biomarkers, and improved microbiology workflows are influencing prescribing behavior by enabling earlier de-escalation or escalation of therapy. Vaccine policy is also reshaping treatment demand by reducing preventable severe disease, particularly through pneumococcal, influenza, respiratory syncytial virus, Haemophilus influenzae type b, and COVID-19 prevention strategies. Hospitals are adopting standardized pathways for community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, and aspiration pneumonia, while outpatient care is increasingly focused on risk stratification, adherence, and minimizing unnecessary antibiotic exposure. These shifts are strengthening the role of evidence-based protocols, real-world surveillance, infection prevention, and multidisciplinary collaboration among infectious disease specialists, pulmonologists, pharmacists, intensivists, microbiologists, emergency physicians, and primary care clinicians.

Cumulative Impact of Artificial Intelligence on Pneumonia Therapeutics

Artificial intelligence is influencing pneumonia therapeutics by improving clinical triage, diagnostic interpretation, antimicrobial decision support, and operational readiness. AI-enabled imaging tools can assist in identifying radiographic features consistent with pneumonia on chest X-rays and CT scans, supporting faster assessment in emergency, hospital, and resource-constrained settings when used with clinician review. Machine learning models are being studied for predicting disease severity, intensive care needs, mortality risk, readmission risk, sepsis progression, and likelihood of treatment failure using clinical variables, laboratory values, oxygenation metrics, imaging findings, and electronic health record data. In antimicrobial stewardship, AI can help flag discordant therapy, identify patients eligible for de-escalation, support local resistance-aware prescribing, and improve timely review of culture and susceptibility results when integrated with microbiology systems. AI also supports drug discovery and repurposing research by screening molecular targets, modeling host-pathogen interactions, prioritizing compounds, and analyzing clinical trial and real-world evidence signals. However, implementation must address algorithmic bias, data quality, explainability, cybersecurity, regulatory validation, workflow integration, and clinician oversight, especially because pneumonia outcomes are highly sensitive to timely and accurate therapeutic decisions.

Key Regional Insights Across Pneumonia Therapeutics

In Asia-Pacific, pneumonia therapeutics are shaped by high respiratory infection burden, dense urban centers, aging populations in several economies, expanding hospital infrastructure, and uneven access to diagnostics, oxygen therapy, and advanced antimicrobial stewardship. Countries with large pediatric and elderly populations continue to prioritize vaccination, early treatment, and improved primary care referral systems, while resistance surveillance remains central to appropriate antibiotic use. Europe emphasizes guideline-driven treatment, vaccination policy, cross-border antimicrobial resistance surveillance, and hospital stewardship, with increasing focus on reducing inappropriate antibiotic use and improving outcomes in older adults, long-term care residents, and patients with chronic disease. North America demonstrates strong adoption of evidence-based clinical guidelines, advanced diagnostic platforms, intensive care protocols, vaccination programs, and antimicrobial stewardship, with pneumonia management closely tied to surveillance of drug-resistant organisms, respiratory virus circulation, and quality improvement initiatives. Latin America faces a dual challenge of improving access to essential antibiotics, oxygen, and respiratory care while strengthening diagnostic capacity and resistance monitoring across public and private health systems. Africa continues to face a substantial pneumonia burden, particularly among children and vulnerable adults, making access to essential medicines, pulse oximetry, oxygen therapy, vaccination, diagnostics, and community-level case management central to therapeutic impact. The Middle East is investing in modern hospital systems, intensive care capacity, infection prevention, and infectious disease preparedness, while pneumonia therapeutics are influenced by population mobility, comorbidity patterns, antimicrobial resistance risks, and access differences across healthcare settings.

Key Group Insights Across Pneumonia Therapeutics

Across NATO member states, pneumonia therapeutics are influenced by emergency preparedness, military medicine, biosecurity planning, and respiratory infection readiness, especially in countries with established hospital networks, stockpiling frameworks, and critical care protocols. G7 countries generally demonstrate advanced regulatory systems, strong clinical research capacity, established vaccination programs, high adoption of stewardship frameworks, and broad access to diagnostics, although aging populations, viral respiratory surges, and drug-resistant infections continue to pressure treatment pathways. BRICS countries represent a heterogeneous but highly consequential group for pneumonia therapeutics, combining large patient populations, domestic pharmaceutical manufacturing capabilities, expanding hospital networks, infectious disease surveillance priorities, and persistent gaps in equitable access to diagnostics, oxygen, and optimized care. The European Union benefits from coordinated health policy mechanisms, antimicrobial resistance action plans, pharmacovigilance systems, vaccination strategies, and harmonized clinical guidance that support prudent antibiotic use and vaccine-based prevention. Across ASEAN, pneumonia therapeutics are influenced by diverse healthcare capacities, tropical infectious disease patterns, antimicrobial resistance concerns, expanding immunization programs, and the need for affordable diagnostics and access to first-line and second-line therapies. GCC countries show growing investment in tertiary care, digital health, infection prevention, and specialized respiratory and critical care services, supporting more protocolized treatment of severe pneumonia, hospital-acquired infections, and pneumonia in patients with complex comorbidities.

Key Country Insights Across Pneumonia Therapeutics

China continues to expand hospital capacity, infectious disease surveillance, vaccination initiatives, and domestic therapeutic capabilities, while pneumonia treatment priorities include antimicrobial resistance control, rapid diagnosis, and improved access in lower-tier cities and rural areas. The United States has a highly protocolized pneumonia therapeutics environment supported by clinical guidelines, broad diagnostic availability, stewardship mandates, vaccination programs, and strong focus on community-acquired, hospital-acquired, and ventilator-associated pneumonia management. Japan's aging population drives demand for pneumonia prevention, aspiration pneumonia management, vaccination, swallowing and long-term care interventions, and careful antibiotic use in acute and long-term care. India faces high pneumonia burden and heterogeneous care access, making affordable antibiotics, oxygen availability, vaccination, diagnostics, referral pathways, and stewardship essential to better outcomes. Germany benefits from strong hospital infrastructure, specialist care, microbiology capacity, and structured antibiotic stewardship, supporting targeted therapy and management of complex pneumonia cases. The United Kingdom emphasizes guideline-led prescribing, national antimicrobial stewardship, vaccination, rapid assessment pathways, and integrated management across primary and hospital care. Australia benefits from strong vaccination programs, stewardship practices, tertiary care capacity, and respiratory surveillance, while rural access and Indigenous health equity remain important considerations. France combines robust public health policy, vaccination initiatives, pharmacovigilance, and hospital-based infectious disease expertise to guide rational treatment and prevention-led care. South Korea demonstrates advanced hospital infrastructure, diagnostics, digital health adoption, infection control practices, and stewardship activity, supporting increasingly precise pneumonia treatment pathways. Italy and Spain have significant older adult populations, making prevention, early diagnosis, vaccination, aspiration risk management, and effective treatment of severe pneumonia especially important in hospital and long-term care settings. Canada emphasizes public health prevention, vaccination, antimicrobial stewardship, and equitable access across geographically dispersed populations, including remote and Indigenous communities. Russia's pneumonia therapeutics environment is influenced by regional healthcare variation, respiratory infection burden, hospital capacity differences, and the need for consistent access to diagnostics and optimized antimicrobial use. Brazil faces substantial respiratory infection burden across diverse regions, with therapeutic priorities centered on vaccination, access to antibiotics, oxygen support, hospital readiness, and resistance surveillance. Mexico is strengthening pneumonia care through expanded public health coverage, immunization efforts, and improved access to essential antimicrobials, while diagnostic variability remains an important treatment consideration.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize pneumonia therapeutics strategies that align clinical efficacy, antimicrobial stewardship, safety, and access. Development and commercialization plans should account for local resistance patterns, guideline recommendations, diagnostic availability, vaccination coverage, and the growing need to distinguish bacterial pneumonia from viral, fungal, aspiration-related, and mixed infections. Stakeholders should invest in evidence generation for high-risk populations, including older adults, children, immunocompromised patients, people with chronic respiratory or cardiovascular disease, and patients in intensive care or long-term care settings. Partnerships with healthcare systems can strengthen stewardship education, pharmacovigilance, real-world outcome tracking, and appropriate use of rapid diagnostics. Organizations should also support treatment adherence programs, oxygen access initiatives, and differentiated formulations suitable for outpatient, inpatient, pediatric, and critical care use. For long-term competitiveness, leaders should focus on resistance-aware innovation, broad geographic access, resilient supply continuity for essential medicines, and clinically meaningful endpoints such as time to clinical stability, reduced complications, shorter hospitalization, lower treatment failure, and improved survival in severe pneumonia.

Research Methodology

This executive summary is developed using a structured secondary research methodology focused on verified public health, clinical, regulatory, and scientific sources. Inputs include international and national pneumonia treatment guidelines, antimicrobial resistance surveillance materials, vaccination policy references, peer-reviewed clinical literature, public health agency publications, regulatory safety communications, essential medicines references, respiratory disease surveillance, and hospital stewardship guidance. The analysis applies source triangulation to compare therapeutic practices across regions, country healthcare contexts, clinical pathways, care settings, and disease types, including community-acquired, hospital-acquired, ventilator-associated, aspiration-related, viral, fungal, and severe bacterial pneumonia. Emphasis is placed on data-backed trends related to treatment protocols, diagnostic adoption, prevention strategies, resistance management, oxygen and supportive care access, and healthcare system readiness. The methodology excludes speculative market sizing, revenue estimation, market share ranking, and forecasting, and instead focuses on evidence-based interpretation of the factors shaping pneumonia therapeutics decisions across healthcare systems.

Conclusion

Pneumonia therapeutics are moving toward faster diagnosis, more precise treatment selection, stronger antimicrobial stewardship, and prevention-led disease reduction. The most important strategic themes include managing antimicrobial resistance, improving access to essential antibiotics and oxygen therapy, integrating rapid diagnostics, expanding vaccination impact, and addressing high-risk patient needs across pediatric, older adult, immunocompromised, chronic disease, and critical care populations. Regional and country-level differences in healthcare infrastructure, public health policy, resistance surveillance, diagnostic capacity, oxygen availability, and affordability continue to shape therapeutic adoption. Artificial intelligence, real-world evidence, digital clinical decision support, and advanced surveillance can enhance pneumonia management when validated and implemented responsibly. For industry stakeholders, the strongest opportunities lie in delivering clinically differentiated, stewardship-compatible, accessible, and supply-resilient solutions that improve patient outcomes across community, hospital, and critical care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pneumonia Therapeutics Market, by Product

  • 7.1. Introduction
  • 7.2. Drugs
    • 7.2.1. Antibiotics
    • 7.2.2. Antivirals
    • 7.2.3. Antifungals
  • 7.3. Vaccines
    • 7.3.1. Pneumococcal vaccines
    • 7.3.2. Influenza vaccines

8. Pneumonia Therapeutics Market, by Mode of Infection

  • 8.1. Introduction
  • 8.2. Community-acquired pneumonia (CAP)
  • 8.3. Hospital-acquired pneumonia (HAP)
  • 8.4. Ventilator-associated pneumonia (VAP)
  • 8.5. Aspiration pneumonia

9. Pneumonia Therapeutics Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Intravenous (IV)
  • 9.4. Intramuscular (IM)
  • 9.5. Inhalation

10. Pneumonia Therapeutics Market, by Age Group

  • 10.1. Introduction
  • 10.2. Pediatric
  • 10.3. Adults
  • 10.4. Geriatric

11. Pneumonia Therapeutics Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Online
  • 11.3. Offline

12. Pneumonia Therapeutics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Pneumonia Therapeutics Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Pneumonia Therapeutics Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. AstraZeneca PLC
  • 16.3. Aurobindo Pharma Limited
  • 16.4. Bayer AG
  • 16.5. Biobrick Pharma Private Limited
  • 16.6. Cipla Limited
  • 16.7. Dr. Reddy's Laboratories Limited
  • 16.8. Eli Lilly and Company
  • 16.9. F. Hoffmann-La Roche Ltd.
  • 16.10. GSK plc
  • 16.11. Hikma Pharmaceuticals PLC
  • 16.12. Lincoln Pharmaceuticals Limited
  • 16.13. Mankind Pharma Limited
  • 16.14. Merck & Co., Inc.
  • 16.15. Novartis AG
  • 16.16. Pfizer Inc.
  • 16.17. Sanofi
  • 16.18. Serum Institute of India Private Limited
  • 16.19. Sun Pharmaceutical Industries Limited
  • 16.20. Teva Pharmaceutical Industries Ltd.
  • 16.21. Viatris Inc.
  • 16.22. Wellona Pharma Private Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMONIA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PNEUMONIA THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PNEUMONIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL PNEUMONIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL PNEUMONIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIFUNGALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMMUNITY-ACQUIRED PNEUMONIA (CAP) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMMUNITY-ACQUIRED PNEUMONIA (CAP) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMMUNITY-ACQUIRED PNEUMONIA (CAP) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HOSPITAL-ACQUIRED PNEUMONIA (HAP) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HOSPITAL-ACQUIRED PNEUMONIA (HAP) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HOSPITAL-ACQUIRED PNEUMONIA (HAP) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA (VAP) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA (VAP) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VENTILATOR-ASSOCIATED PNEUMONIA (VAP) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ASPIRATION PNEUMONIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ASPIRATION PNEUMONIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ASPIRATION PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAMUSCULAR (IM) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAMUSCULAR (IM) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRAMUSCULAR (IM) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 120. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 121. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 122. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 123. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 129. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 130. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 131. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 160. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 162. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 185. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 186. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 187. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 188. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 193. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 194. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 195. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 196. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 201. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 202. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 203. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 204. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 217. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 218. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 219. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 220. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 225. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 226. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 227. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 228. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 233. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 234. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 235. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 236. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 241. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 242. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 243. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 244. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 252. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 257. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 258. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 259. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 260. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 281. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 282. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 283. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY MODE OF INFECTION, 2018-2032 (USD MILLION)
  • TABLE 284. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. GLOBAL PNEUMONIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 288. GLOBAL PNEUMONIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025